Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dosing recommendations for encainide.

M J Antonaccio, S Verjee

    The American Journal of Cardiology
    |August 29, 1986
    PubMed
    Summary

    Encainide effectively treats ventricular arrhythmias, with optimal results seen after 14 days of dosing. Doses of 75 mg/day or more are needed for significant arrhythmia reduction, but higher doses increase side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization.

    Transfusion medicine (Oxford, England)·2004
    Same author

    Evaluation of Cobe Trima for the collection of blood components with particular reference to the in vitro characteristics of the red cell and platelet concentrates and the clinical responses to transfusion.

    Transfusion science·2000
    Same author

    Evolution of technology in the managed care environment.

    Journal of healthcare information management : JHIM·1999
    Same author

    Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia (FMAIT).

    British journal of haematology·1999
    Same author

    Stanniocalcin: a novel protein regulating calcium and phosphate transport across mammalian intestine.

    The American journal of physiology·1998
    Same author

    Urokinase-type plasminogen activator stimulates wound healing in the diabetic mouse.

    Inflammation research : official journal of the European Histamine Research Society ... [et al.]·1997

    Area of Science:

    • Pharmacology
    • Cardiology

    Background:

    • Ventricular arrhythmias pose a significant risk to patients.
    • Effective antiarrhythmic drug therapy is crucial for managing these conditions.

    Purpose of the Study:

    • To evaluate the efficacy and safety of encainide in treating ventricular arrhythmias.
    • To determine optimal dosing strategies for encainide therapy.

    Main Methods:

    • Conducted 5 well-controlled studies with 331 patients.
    • Assessed antiarrhythmic activity after single and multiple doses of encainide (10, 25, 50, 75, and up to 200 mg/day).
    • Monitored arrhythmia reduction and patient response over 24-hour periods.

    Main Results:

    • Encainide demonstrated a dose-related decrease in ventricular arrhythmias.
    • Doses of 25-50 mg three times daily for 14 days abolished or decreased arrhythmias.
    • Efficacy plateaued above 200 mg/day, with increased side effects at doses >= 150 mg/day.

    Conclusions:

    • Encainide is an effective antiarrhythmic agent for ventricular arrhythmias.
    • Initiate encainide at 25 mg TID, titrating as needed, and avoid rapid escalation or doses > 200 mg/day.
    • Patients with severe arrhythmias require cardiac monitoring and advanced life support.

    Related Experiment Videos